Sulfa during pregnancy.
TMP-SMX use in pregnancy is shaped by two specific concerns. Trimethoprim is a folate antagonist, and first-trimester exposure has been associated with neural tube and other defects in some studies. Sulfamethoxazole near term carries a theoretical risk of kernicterus (bilirubin displacement) in the newborn. Decisions are case-by-case and made with obstetric input.
- First trimester
- Folate antagonism (TMP) — neural tube and other defect signal in some observational studies.
- Late pregnancy
- Sulfa drugs displace bilirubin from albumin — theoretical kernicterus risk in the newborn.
- Mid-pregnancy
- Generally less restricted than the first or late thirds, though decisions remain individual.
- Decision
- Always with obstetric input; the indication for the drug matters.
The first-trimester concern
Trimethoprim — the second component of sulfamethoxazole/trimethoprim — inhibits dihydrofolate reductase. That is the same enzyme inhibited (more potently) by methotrexate and pyrimethamine. Folate is critical to the closure of the neural tube in the first weeks of pregnancy. Inhibiting folate metabolism around that window has been a theoretical concern for decades, and observational studies have produced signals — though not perfectly consistent ones — for an association between first-trimester TMP-SMX exposure and neural tube defects, cardiovascular defects, and oral clefts.
The absolute increase in risk in published data is modest. Many women with first-trimester TMP-SMX exposure have uncomplicated pregnancies. Folic acid supplementation, recommended for all reproductive-age women considering pregnancy, is particularly relevant in this context.
In current obstetric practice, TMP-SMX is generally avoided in the first trimester unless no suitable alternative exists. The decision considers the indication: an unequivocal need (e.g. Pneumocystis jirovecii pneumonia in an immunocompromised pregnant patient) tilts toward use; a more flexible indication (uncomplicated UTI, where alternatives such as nitrofurantoin or fosfomycin are available) tilts toward an alternative.
The late-pregnancy concern
Sulfamethoxazole and other sulfa antibiotics displace bilirubin from albumin-binding sites. In adults this rarely matters. In the newborn — especially the preterm or low-birthweight newborn, with immature liver bilirubin handling — displacement can raise unconjugated bilirubin, and very high unconjugated bilirubin can cross into the brain and cause kernicterus, a permanent neurological injury.
The risk is theoretical for an exposed fetus but real for a newborn directly exposed (through breast milk, in some scenarios, or through perinatal transfer). Sulfa antibiotics are therefore generally avoided in the last weeks of pregnancy and in the first weeks of life. Nitrofurantoin is also avoided in late pregnancy for a related (but different — hemolysis) concern.
Mid-pregnancy
The middle of pregnancy carries less of either specific concern than the first trimester (organogenesis) or the last weeks (kernicterus). TMP-SMX is sometimes used in this window when needed, with attention to the indication and to alternatives. Decisions are made by the obstetric team with the prescriber.
Sulfasalazine and other sulfa-family drugs
Sulfasalazine has been used in pregnancy in patients with active inflammatory bowel disease or rheumatologic disease where treatment is needed. Folate supplementation is typically given because of the folate-antagonist effect of the drug. The decision is made in conjunction with the gastroenterologist or rheumatologist and the obstetrician.
The non-antibiotic sulfonamides — furosemide, HCTZ, celecoxib, sulfonylureas, acetazolamide — each have their own pregnancy considerations independent of the sulfa label. Most are not first-line in pregnancy: thiazides are sometimes used for chronic hypertension (with caveats); loop diuretics are reserved for specific indications; sulfonylureas are not first-line in gestational diabetes (insulin and metformin are typically preferred); celecoxib and other NSAIDs are generally avoided in the third trimester (premature ductus arteriosus closure, oligohydramnios). These decisions belong to the obstetric and prescribing teams.
Allergy in pregnancy
A sulfa allergy label in pregnancy is treated as it would be outside pregnancy — most labels refer to past sulfa antibiotic reactions. The relevance is to the choice of antibiotic when an infection arises (UTI, MRSA infection). Many pregnancy-friendly alternatives exist for these indications, so a sulfa allergy is rarely a decisive constraint.
Breastfeeding
Sulfa antibiotics pass into breast milk in small amounts. For healthy term newborns, short courses of TMP-SMX in lactating mothers are usually considered acceptable. Breastfeeding a preterm or jaundiced newborn while on a sulfa antibiotic raises the same kernicterus concern that applies to late pregnancy, and is generally avoided. The decision belongs to the prescriber.
Folic acid
For all women planning pregnancy, daily folic acid supplementation is widely recommended (400 micrograms in most guidelines for low-risk pregnancies, higher in some specific situations). The recommendation is independent of any antibiotic exposure. Adequate folate stores reduce the baseline risk of neural tube defects regardless of medications used.